About Abliva AB

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Company Highlights
Year Founded

2000

icon-altEmployees

12

Location (HQ)

SWE

Since Last Funding

2 years 3 months

Monthly Website Visitors

14.7K

icon-altTotal Investment Amt

$40M

Last Funding Round

Post Ipo Equity

icon-altYoY Headcount Growth

-7.63%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Pharmaceutical Manufacturing

Pharmaceuticals

Clinical Trials